SHREYA CARMEN PAL



DATOS GENERALES NOMBRAMIENTOS
Nombre completo   SHREYA CARMEN PAL
Máximo nivel de estudios  
Antigüedad académica en la UNAM   1 año, 4 meses, 29 días

Último  AYUDANTE PROFESOR A TP No Definitivo
Facultad de Medicina
ESTIMULOS, PROGRAMAS, PREMIOS Y RECONOCIMIENTOS
NO CUENTA CON ESTIMULOS, PROGRAMAS, PREMIOS Y RECONOCIMIENTOS

INFORMACIÓN DE PUBLICACIONES
Firmas  
Pal S.C. Pal, Shreya C.
Áreas de conocimiento  
Endocrinology and metabolism Gastroenterology and hepatology Genetics and heredity Medicine, research and experimental Pharmacology and pharmacy
Endocrinology, diabetes and metabolism Genetics Hepatology Medicine (miscellaneous)
Coautorías con entidades de la UNAM  
Revistas en las que ha publicado  (9):
  1. Annals Of Hepatology, México (2023)
  2. EXPERT OPINION ON PHARMACOTHERAPY, Reino Unido (2023)
  3. GENES, Suiza (2023)
  4. HEPATOLOGY INTERNATIONAL, Estados Unidos America (2023)
  5. HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, Grecia (2022)
  6. JOURNAL OF HEPATOLOGY, Países Bajos (2022)
  7. MEDICAL SCIENCE MONITOR, Estados Unidos America (2022)
  8. Therapeutic Advances in Endocrinology and Metabolism, Estados Unidos America (2023)
  9. WORLD JOURNAL OF GASTROENTEROLOGY, Estados Unidos America (2023)


Documentos indexados (WoS y Scopus)

# Título del documento Autores Año Rista Fuente Citas WoS Citas Scopus
1MAFLD: perceived stigma?a single-center Mexican patient survey2ᵒ autor: Pal S.C., Méndez-Sánchez N., Fassio E., Díaz-Ferrer J., et al.2023HEPATOLOGY INTERNATIONALWoS-id: 000894544400002
Scopus-id: 2-s2.0-85143440740
17
2Interpretive bias on research evidence: Striving to meet the trustworthiness criteriaCoautor y autor de correspondencia: Pal, Shreya C., Mendez-Sanchez, Nahum, Fassio, Eduardo2023Annals Of HepatologyWoS-id: 000899935000001
Scopus-id: 2-s2.0-85145691527
00
3How far are we from an approved drug for nonalcoholic steatohepatitis?2ᵒ autor: Pal S.C., Méndez-Sánchez N., Córdova-Gallardo J.2023EXPERT OPINION ON PHARMACOTHERAPYWoS-id: 000979181200001
Scopus-id: 2-s2.0-85158817329
02
4Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis1ᵉʳ autor: Pal, Shreya C., Mendez-Sanchez, Nahum2023WORLD JOURNAL OF GASTROENTEROLOGYWoS-id: 001032674900004
Scopus-id: 2-s2.0-85164987251
011
5Screening for MAFLD: who, when and how?1ᵉʳ autor: Pal, Shreya C., Mendez-Sanchez, Nahum2023Therapeutic Advances in Endocrinology and MetabolismWoS-id: 001061086400001
Scopus-id: 2-s2.0-85147034404
26
6Molecular Mechanisms Involved in MAFLD in Cholecystectomized Patients: A Cohort Study1ᵉʳ autor: Pal, Shreya C., Castillo-Castaneda, Stephany M., Diaz-Orozco, Luis E., Ramirez-Mejia, Mariana M., et al.2023GENESWoS-id: 001093717500001
Scopus-id: 2-s2.0-85175272849
01
7Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?2ᵒ autor y autor de correspondencia: Pal S.C., Mendez-Sanchez N.2022MEDICAL SCIENCE MONITORWoS-id: 000811725500001
Scopus-id: 2-s2.0-85132080107
26
8Detangling the interrelations between MAFLD, insulin resistance, and key hormones1ᵉʳ autor: Pal, Shreya C., Eslam, Mohammed, Mendez-Sanchez, Nahum2022HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISMWoS-id: 000835599300001
Scopus-id: 2-s2.0-85135341662
2021
9Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity2ᵒ autor: Pal, Shreya C., Barranco-Fragoso, Beatriz, Diaz-Orozco, Luis E., Dorantes-Heredia, Rita, et al.2022MEDICAL SCIENCE MONITORWoS-id: 000841909000001
Scopus-id: 2-s2.0-85135549674
24
10Correction to: Detangling the interrelations between MAFLD, insulin resistance, and key hormones (Hormones, (2022), 21, 4, (573-589), 10.1007/s42000-022-00391-w)1ᵉʳ autor: Pal, Shreya C., Eslam, Mohammed, Mendez-Sanchez, Nahum2022HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISMWoS-id: 000846799600001
Scopus-id: 2-s2.0-85136631968
00
11Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)Coautor: Pal, Shreya C., Ordóñez-Vázquez A.L., Beltrán-Gall S.M., Mendez-Sanchez, Nahum2022MEDICAL SCIENCE MONITORWoS-id: 000861215900002
Scopus-id: 2-s2.0-85137658129
47
12New terms for fatty liver disease other than MAFLD: Time for a reality check2ᵒ autor y autor de correspondencia: Pal, Shreya C., Mendez-Sanchez, Nahum2022JOURNAL OF HEPATOLOGYWoS-id: 000899473900021
Scopus-id: 2-s2.0-85141673462
14

Descargar PDF